Navigation Links
CardiacAssist, Inc. Announces Record Breaking Site Activity and Financial Results
Date:11/5/2008

PITTSBURGH, Nov. 5 /PRNewswire/ -- CardiacAssist, Inc. announced that it reached a new high of more than 75 sites with the TandemHeart System performing at least one TandemHeart case during the third quarter of 2008. In addition, the quarter ending September 30th showed the highest year on year growth in case activity with a leap of 64 %. Revenue and income also showed significant increase of 70 % and 497 %. Through nine months of 2008, CardiacAssist has also set records in revenues, net income and cash flow by wide margins.

The TandemHeart is often selected for its high net flow rate of up to 5 lpm in the Cath Lab or up to 8 lpm in the OR as well as its flexibility and rapid deployment potential. Many centers are implementing the TandemHeart as part of their standard of care especially when the traditional IABP and medical therapy is deemed inadequate. When considering valve procedures and right heart cases that can not be supported by any other devices, the TandemHeart is the only percutaneous solution and has been used by more than 40 centers in this way.

More than 130 hospitals worldwide now use the TandemHeart System in the Cath Lab and/or Operating Room for extracorporeal circulatory support.

There are a variety of FDA cleared devices that provide extracorporeal circulatory support, but all others offer less than half the net flow and hemodynamic support of the TandemHeart. The TandemHeart is the only 5 lpm net flow, percutaneous "extracorporeal circulatory support" device approved by the FDA for sale in the U.S. Other devices including Impella 2.5 are labeled by the FDA to be used for "partial circulatory support" with less than 2.5 lpm net flow.

Many TandemHeart Centers are boldly moving ahead in saving lives and expanding the effectiveness of their circulatory support program. There are currently 16 Centers that have completed 20 or more cases. Not only are they recognized names such as Texas Heart Institute, Brigham & Women's, Johns Hopkins and Montefiore using the TandemHeart, but regional and community hospitals are also recognizing the benefits that the Tandem Heart System can provide their patients. Because of this widespread usage the 1,500th TandemHeart case will soon be performed.

Three new centers have also added the TandemHeart System to their Cath Lab or OR. The new TandemHeart Centers of Excellence are:

• Christus St. Patrick Hospital, Lake Charles, LA

• Shawnee Mission Medical Center, Shawnee Mission, KS

• Louis Stokes VA Cleveland Medical Center, Cleveland, OH

The TandemHeart is fully reimbursed by Medicare under existing DRG codes. The device can be placed rapidly in the cath lab or operating room, providing effective, reliable, temporary circulatory support. To date, the TandemHeart has been used in 28 countries by 125 different facilities by 300 different physicians.

Monica Bush

Marketing Specialist

Ph: 412-963-7770 ext. 247

mbush@cardiacassist.com


'/>"/>
SOURCE CardiacAssist, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. CardiacAssist, Inc. Announces Five New TandemHeart Centers of Excellence
2. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
3. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
4. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
5. HEI, Inc. Announces Sale of RFID Division Assets
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
7. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
8. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
9. Brooke Franchise Corporation Announces Selected July Results
10. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... Vegas, Nevada (PRWEB) , ... June 24, 2016 ... ... Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing ... Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
Breaking Medicine Technology: